OBJECTIVES: To determine the relative risks of long-term mortality between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) among patients with end-stage renal disease (ESRD).
INTRODUCTION
Prior studies [1, 2] have noted differences in the relative risk of longterm mortality between coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) among patients with endstage renal disease (ESRD). These disparities appear to be largely related to the size of the study and the extent of statistical risk adjustment [1] . Including large studies that utilized the United States Renal Data System (USRDS), the median sample size has been 120. The aim of our study is to assess mortality and repeat coronary revascularization outcomes between CABG and PCI in a well-described, moderate-sized cohort of patients on chronic dialysis.
MATERIALS AND METHODS

Source and target population
Our source population included members of Kaiser Permanente Northern California (KPNC), a large integrated health-care delivery system that provides comprehensive care to greater than 3.3 million members across the San Francisco Bay Area. Our target population included adult members receiving chronic dialysis identified from a comprehensive health plan ESRD treatment registry who underwent coronary revascularization by either PCI or CABG. Historically, CABG and PCI procedures have been performed predominantly in three centres. Our current dataset did not have the record of the facility at which the procedures were performed. However, we did have the facility from which patients were referred and we accordingly made statistical adjustments for this (see the Statistical Analysis section). The study extended from 1 January 1996 to 31 December 2008. We identified a coronary revascularization procedure based on procedure codes for CABG or PCI (furnished upon request) without a concomitant valve or other cardiac surgical procedure. Patients were followed until death or they were censored when they met any of the following criteria: end of study as of 31 December 2008, organ transplantation or disenrollment from the health plan. This study was approved by the Northern California Kaiser Foundation Research Institute's Institutional Review Board. A waiver of informed consent was obtained due to the nature of the study.
Outcomes and covariates
The primary outcome, all-cause mortality, and the secondary outcome, repeat revascularization, were ascertained using health plan databases, state death certificates and social security administration files up to December 2008 which was the latest available complete vital status data at the time of the planned analysis. For our primary outcome mortality, 499 reached the end of study and 516 patients died. Through the Kaiser Permanente and Social Security Death databases, we were able to ascertain mortality in all patients. However, for the secondary outcome, repeat revascularization, 10.2% were lost to follow-up. Our primary predictor was CABG.
We obtained information from health plan clinical and administrative databases on patient demographic characteristics, clinical characteristics, selected laboratory data and medication exposure using previously described approaches [3] [4] [5] . The baseline clinical comorbidities were obtained using International Classification of Diseases, Ninth edition (ICD-9) codes. The clinical variables included were baseline demographics (age at index revascularization, gender, race and duration of dialysis prior to index revascularization) and baseline comorbidities [history of tobacco use, myocardial infarction, heart failure, diabetes mellitus, hypertension, hyperlipidaemia, liver disease, lung disease, stroke/transient ischaemic attack, atrial fibrillation/flutter (codes available upon request) and baseline medications (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium-channel blockers, diabetes mellitus medications, HMG-CoA reductases (statins) and nitrates]. The above baseline clinical and medication variables that were obtained had similarities to those used in recent studies [6, 7] . Most of the angiographic variables, such as the type of stent (bare metal or drug-eluting) used and the number of vessels involved in the index revascularization (CABG or PCI), were obtained from procedure codes (available upon request). Individual patient chart review was also performed and data were also abstracted from surgical or PCI procedure reports.
Statistical analyses
All statistical analyses were performed using STATA version 13 (StataCorp, College Station, TX, USA). Initial bivariate analysis of baseline variables was compared by the revascularization modality that was performed using the Fisher's exact test for categorical variables and a non-parametric test, i.e. Kruskal-Wallis rank test, for continuous variables. Time-to-event analysis was performed using the Kaplan-Meier method. Multivariable Cox regression models were created to estimate the hazard ratios (HRs) and 95% confidence interval (CI) for the primary predictor under the assumption of independent censoring [8] with a robust variance estimate that adjusts for within-cluster (facility) correlation [9] . Finally, we used a Fine-Gray model for an analysis of the secondary outcome repeat revascularization when the competing risk was mortality [8] . We then graphed the cumulative incidence function stratified by CABG or PCI. A P-value of <0.05 was used as the statistical threshold for significance.
RESULTS
Baseline clinical characteristics
Patient entry into the study is shown in Fig. 1 . There were no differences in age between those referred to CABG or PCI (P = 0.06). However, the probability of referral to CABG peaked around the age of 67 years. There were more men referred for CABG and PCI than women (P < 0.001). At baseline, the CABG group had a higher proportion of diabetics (P = 0.045), higher nitrate use (P = 0.01) and a higher number of vessels intervened upon (P < 0.001; Table 1 ). As this study extended during 1998-2006, bare metal stents constituted 37.8%, while drug-eluting stents constituted 63.2% of the total PCI group. Temporal trends in the revascularization type and outcomes during the study period have been described before [10] .
Mortality
The incidence rates for the primary outcome of all-cause mortality per 1000 person-years for PCI (255.5, 95% CI, 227.1-287.4) and CABG (252.4, 95% CI, 222.3-286.6) were similar. The KaplanMeier curve for all-cause mortality stratified by revascularization status is shown in Fig. 2 . The unadjusted HR of CABG for 1-year mortality was 0.94 (95% CI, 0.71-1.24) and for 1-5 years was 0.84 (95% CI, 0.54-1.29) with an overall unadjusted HR of 0.75 (95% CI, 0.46-1.22). Adjusted for the year of index revascularization, age, duration of dialysis prior to index revascularization as continuous linear variables, sex, race, number of vessels intervened and baseline comorbidities as noted in the Materials and Methods section, we found that, during the first year of follow-up, patients referred for CABG had a slight non-significant increase in the hazard (HR 1.16, 95% CI, 0.80-1.67) of mortality compared with PCI. Between Years 1 and 5, there was a 9% non-statistically significant decrease in the hazard (HR 0.91, 95% CI, 0.63-1.33) with an overall nonsignificant HR of 0.73 (95% CI, 0.43-1.22) with CABG compared with PCI. We have described gender-based cardiovascular outcomes as well as a possible biologically based interaction between sex and type of revascularization in a prior study [11] .
Repeat revascularization
The incidence rates for repeat revascularization per 1000 personyears for PCI (147.1, 95% CI, 123.4-175.2) were lower when compared with CABG (46.4, 95% CI, 34.1-63.3). The unadjusted hazard for repeat revascularization was 0.34 (95% CI, 0.23-0.48). The adjusted sub-HR was 0.49 (95% CI, 0.29-0.82) as calculated by the Fine-Gray competing risk model, when the competing risk was mortality. The cumulative incidence function graph is shown in Fig. 3 .
Risk factors for mortality and repeat revascularization
In Table 2 , we show risk factors for the primary and secondary outcomes. Increasing age, prior myocardial infarction, diabetes mellitus and atrial fibrillation and presence of liver disease were strongly associated with worse mortality outcomes. Furthermore, advancing year of index revascularization, race and duration of dialysis were associated with improved survival. Only the receipt of CABG was associated with a decrease in repeat revascularization.
DISCUSSION
In patients with ESRD and established coronary artery disease, our study demonstrated, similar to prior large-sized observational studies [7] but with decreased precision, an initial 16% nonsignificant increase in mortality in Year 1 and a 9% non-significant decrease in mortality between Years 1 and 5 with an overall relative risk that crossed 1, suggesting equivalency between CABG and PCI. We also showed that there was a 51% significant decrease 
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of repeat coronary revascularization with CABG compared with PCI when the competing risk was death.
There have been no randomized clinical trials in this area. Most prior observational studies have been small with a median sample size of 120 [1, 2, 12] . Many have shown the superiority of CABG [2, 6, 13, 14], whereas others have suggested that PCI may be a suitable initial strategy [15] . Some have suggested that there continues to be insufficient data to make firm conclusions due to variations in the covariates used for statistical risk adjustment [1] or due to the paucity of angiographic data available in observational studies [6] . None have focused on issues surrounding frailty [16] or variables that may partially simulate the surgeon's 'eyeball test' [17] . The variations noted above have resulted in significant heterogeneity noted in meta-analyses [1, 2] . Overall, considering the inherent limitations of observational studies, the body of evidence suggests that there is an 7-10% reduction of long-term mortality with CABG compared with PCI [1, 2] . Our moderate-sized study, despite its decreased precision, noted a similarity in the direction and magnitude of the effect size.
Of importance in observational studies is attention to the covariates used in risk adjustment and the need for standardization. Of the six covariates used in two smaller studies [18, 19] , age was the only common covariate. Two large studies [13, 14] from the same group using the USRDS database showed variations in the covariates used for statistical adjustment. Prior acute myocardial infarction, coronary revascularization, CABG, stent and cancer were the covariates used in the 2002 study [14] . The variable categorized year of revascularization was used only in the 1999 study Model included age, gender, race, duration of dialysis prior to index revascularization, year of revascularization, number of vessels intervened upon and baseline comorbidities as noted in the Materials and Methods section. [13] . In a recent elegantly performed propensity score analysis, Chang et al. [7] demonstrated a significant 13% lower relative risk of mortality and a significant 12% relative risk reduction in the composite endpoint of death or myocardial infarction with CABG. The covariates used in their analysis were extensive and were described well. In comparison with the Chang study, our covariates were not as extensive. However, despite these variations, our Kaplan-Meier curve was similar to that obtained by Chang et al. Future well-conducted observational studies in this area will need to have a sufficiently robust sample size, standardization in the number, type and definition of covariates as well as including angiographic variables [6] to improve their validity.
One recent small-sized study [12] of 388 patients attempted to improve on prior studies and was able to include angiographic variables in their analysis. In a selected group of ESRD patients with left main disease and multivessel coronary artery disease, they noted no difference in all-cause death between those referred for CABG and PCI. However, they found a significant increase in cardiac death and sudden death with PCI compared with CABG. This finding will need to be further validated in future studies. On the realization of the lack of randomized clinical trials in this area [20] , the National Institutes of Health ISCHEMIA-CKD [21] trial has been initiated. Although it will not directly deliver a comparative effectiveness answer between CABG and PCI such as the FREEDOM [22] study brought to diabetics, it will shed some light into these muddy waters. However, if the past is reflective of the future, further insights in this field will be obtained primarily by observational studies. There is then a mandate for standardization in the numbers and types of covariates used as well as the statistical methodology employed including the use of modern techniques of causal modelling [8] .
CONCLUSIONS
In a cohort of 1015 patients with ESRD referred for coronary revascularization, we demonstrated in the current study that CABG is at least equivalent to PCI for the primary outcome of all-cause mortality with a possible trend towards benefit. Furthermore, in concordance with prior studies, CABG was associated with a 51% significant decrease in the relative risk of repeat revascularization when the competing risk was death.
LIMITATIONS
Overall, it appears that physicians within KPNC have chosen reasonably well the revascularization modality that they felt was best for their patients. The strengths of this study include comprehensively captured clinical characteristics and longitudinal care through the KPNC electronic medical records that provide a more detailed characterization of the study sample than claims data. Ascertainment of the primary outcome relied on multiple sources and previously validated methods. Our study was consistent with almost all prior studies in its limitations. We were not able to obtain angiographic variables and the specific indications for referral to cardiac catheterization. Furthermore, with an understanding that we may not be able to completely overcome confounding by indication, future studies in this specific area will need to collect variables that relate to frailty [16] and hopefully improve on the surgeon's 'eyeball test' [17] . These variables were not able to be captured in the present study and we believe, if present, these would have further refined the model. Future studies will need larger sample sizes to detect the small difference in effect sizes for which the current study may have been underpowered.
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